Latest news with #DiversionControlDivision
Associated Press
a day ago
- Business
- Associated Press
DEA Diversion Officials Scrambling For DOGE Retirement: Corrupt Bureaucrats Blocked Medical Cannabis Research While Patients Suffered
Retirements Reported in DEA's DIVERSION as 'DOGE CASUALTIES'. DEA Faces Scrutiny Over Delays in Medical Cannabis Research. As MMJ BioPharma Cultivation unleashes a legal reckoning, the DEA's unconstitutional Administrative Law system collapses under Supreme Court rulings -forcing Department Of Justice to retreat, leaving DEA officials scrambling for cover. DEA diversion officials will be remembered on its " wall of DISHONOR " for blocking marijuana medicine to suffering patients in need. WASHINGTON, D.C / ACCESS Newswire / June 29, 2025 / The U.S. Drug Enforcement Administration (DEA) is reeling from a constitutional crisis as its controversial Administrative Law Judge (ALJ) system crumbles under Supreme Court rulings, while MMJ BioPharma Cultivation intensifies its legal battle against the agency's alleged sabotage of medical cannabis research. The fallout has triggered retirements and disciplinary actions within the DEA's Diversion Control Division, with insiders dubbing the removed officials 'DOGE Casualties' a nod to their NON alignment with Trump-era policies that prioritized science over obstruction. The DEA's 'Last Stand": An Unconstitutional Tribunal Defies the Supreme Court For over 2,387 days, MMJ BioPharma Cultivation, a company developing FDA sanctioned cannabis therapies for Huntington's Disease and Multiple Sclerosis, has been trapped in the DEA's Administrative Law hearing process. The exact system the Supreme Court declared unconstitutional in Axon Enterprise v. FTC (2023) and Jarkesy v. SEC (2024). These rulings found such agency tribunals violate: In February 2025, the DOJ conceded the system's illegality, refusing to defend it in court. Yet in June, DEA Chief ALJ John Mulrooney II doubled down, denying MMJ's application without a hearing, blocking evidence, and relying on ex parte - communications, a move MMJ CEO Duane Boise called 'bureaucratic mutiny'. 'The DOJ admits the system is illegal, yet the DEA keeps using it to punish medical research,' Boise stated. 'This is a shadow court operating in defiance of the Constitution.' The 'DOGE Casualties": DEA's Diversion Division Implodes High-ranking officials linked to the Trump era Department of Government Efficiency (DOGE) initiative are now facing involuntary retirements or disciplinary action, including: The Irony: 'The DEA had time to sabotage a lawful company but no time to shut down Chinese Communist Party linked farms. That's not negligence; it's systemic failure,' Boise said. DEA Violated Its Own Policy Manual MMJ's treatment flouted the DEA's own Training and Policy Manual, which mandates: 'The DEA's own manual proves this wasn't just delay; it was sabotage,' Boise noted. The Fallout: Legal, Political, and Human Costs MMJ's lawsuit could dismantle the DEA's Administrative Law system entirely, while pressure mounts to: The Human Toll: The DEA Road Ahead: A Test for New Leadership With Terrance Cole nominated as DEA Administrator, advocates demand: 'The DEA is a constitutional dead man walking,' Boise declared. 'Every day it clings to this system, the DEA digs its grave deeper.' A DEA Legacy on the Line As the MMJ BioPharma Cultivation lawsuit advances, the stakes extend beyond one company. The outcome may determine whether the DEA: Either way, the agency's future and the credibility of American drug policy now hangs in the balance. As MMJ's case advances, the DEA's legacy may be defined by its defiance of the courts and the patients it failed. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
Yahoo
03-04-2025
- Business
- Yahoo
DEA's Diversion Division - Patterns of MMJ's Marijuana Court Case Obstruction, Bias, and Corruption
DEA Patterns of Obstruction and Corruption MMJ Alleged in Court Hearing: Spotlight on DEA officialsAnne Milgram, Thomas Prevoznik and Matthew Strait WASHINGTON, DC / / April 3, 2025 / The U.S. Drug Enforcement Administration (DEA) is currently under intense scrutiny following allegations of systematic obstruction and corruption within its Diversion Control Division. Central figures in these allegations include Anne Milgram, past DEA Administrator, Thomas Prevoznik Deputy Administrator and Matthew Strait Policy Administrator, and other senior officials within the division, whose actions are now being questioned in light of ongoing legal challenges and accusations from industry stakeholders. Background of Allegations The Diversion Control Division, responsible for regulating controlled pharmaceuticals and processing MMJ BioPharma Cultivations API Bulk Manufacturing Application, has been accused of deliberately delaying and obstructing the approval processes for companies attempting to conduct legitimate medical research. Duane Boise CEO of MMJ International Holdings, specifically, has pointed to these obstructionist tactics in its lawsuit against the DEA, highlighting the agency's failure to process its applications for cannabis research intended for treatments of Multiple Sclerosis (MS) and Huntington's Disease (HD). Specific DEA Allegations Against Thomas Prevoznik and Matthew Strait Thomas Prevoznik and Matthew Strait have been implicated in what appears to be a broader pattern of behavior that critics label as both obstructive and corrupt. These allegations include: Unjustified Delays: MMJ International Holdings claims that these officials have been instrumental in the multi-year delays of their application to cultivate pharmaceutical-grade marijuana, necessary for their ongoing clinical trials. Manipulative Practices: Accusations extend to manipulative legal and administrative practices aimed at stalling or derailing the approval processes. This includes alleged misinterpretations of regulatory requirements and the arbitrary application of standards not uniformly imposed. Judicial Reactions and Legal Implications The actions of Prevoznik, Strait, and other DEA officials have not only drawn criticism from the companies affected but have also led to judicial rebuke. Recent court proceedings have spotlighted the possible defiance of judicial orders by DEA administrators, as highlighted in the case where DEA Administrator Anne Milgram was accused of instructing attorneys to disregard a court order. This incident has raised serious questions about the integrity of the DEA's regulatory processes and the legality of its internal directives. Systemic Issues Within the DEA The allegations against Prevoznik and Strait are symptomatic of what many critics describe as a systemic issue within the DEA's Diversion Control Division. This includes: Cultural Resistance to Cannabis Research: Despite changing laws and societal attitudes towards cannabis, elements within the DEA reportedly maintain a prohibitionist stance that is increasingly at odds with federal and state policies. Conflicts of Interest: The DEA's role in both policing illegal drug use and regulating pharmaceutical research creates inherent conflicts of interest, particularly when it comes to substances like cannabis, where the agency's enforcement priorities may unduly influence its regulatory decisions. President Trump Calls for Reform In response to these ongoing issues, there are growing calls for substantial reforms within the DEA, particularly concerning its handling of cannabis research. Proposals include: Restructuring the Diversion Control Division: Advocates suggest restructuring the division to better separate its enforcement and regulatory functions. Enhanced Oversight and Transparency: Increasing oversight from independent bodies or federal courts and improving transparency in the regulatory processes. Future Outlook As legal proceedings continue and more details emerge, the actions of Thomas Prevoznik, Matthew Strait, and other associated DEA officials will remain under a microscope. The outcome of these cases could lead to significant changes in how the DEA manages its responsibilities and could influence broader federal policies regarding drug enforcement and pharmaceutical research. The ongoing scrutiny of the DEA's Diversion Control Division highlights a critical moment in U.S. drug policy, particularly concerning the balance between enforcement and facilitating medical advancements. Stakeholders across the pharmaceutical and legal landscapes are closely monitoring these developments, recognizing their potential to reshape the future of drug research and regulation in the United States. MMJ is represented by attorney Megan Sheehan. CONTACT:Madison Hiseymhisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire Sign in to access your portfolio
